Corcept Therapeutics (NASDAQ:CORT) CEO Joseph K. Belanoff disposed of 26,198 shares of the companys common stock on March 25, 2026, bringing in roughly $1.3 million. The trades executed at prices between $50.00 and $50.32 per share and were conducted under a pre-arranged Rule 10b5-1 trading plan that Belanoff adopted on November 26, 2024.
Following the disposition, Belanoff still holds an indirect stake of 2,918,326 shares through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.
Market movement since the sale has been notable. The shares have declined to $37.63 and are down 54% over the past six months, according to InvestingPro data. That same InvestingPro Fair Value assessment now indicates the company is undervalued based on its methodology.
Alongside the insider transaction, Corcept has reported a significant regulatory development. The U.S. Food and Drug Administration granted approval for Lifyorli as a treatment option for adults with platinum-resistant ovarian cancer. The authorization arrived ahead of schedule and marks Lifyorli as the first FDA-approved selective glucocorticoid receptor antagonist. The approval decision was supported by data from the ROSELLA trial, which enrolled 381 patients.
Market and analyst responses have followed. Wolfe Research moved its rating on Corcept to Peerperform from Underperform after the regulatory announcement. At the same time, the company is confronting legal action: a securities class action lawsuit filed by Kahn Swick & Foti targets investors who purchased Corcept shares between October 2024 and December 2025.
Insiders activity has been mixed. In a separate transaction, Corcepts director G. Leonard Baker Jr. purchased 100,000 shares, increasing his direct holdings in the company.
Key points
- CEO Joseph K. Belanoff sold 26,198 shares on March 25, 2026, for about $1.3 million at $50.00 to $50.32 per share.
- Corcept received FDA approval for Lifyorli for adults with platinum-resistant ovarian cancer based on the 381-patient ROSELLA trial; the approval is the first for a selective glucocorticoid receptor antagonist.
- The company faces a securities class action covering purchases from October 2024 through December 2025, and an analyst upgraded the stock to Peerperform from Underperform; director G. Leonard Baker Jr. bought 100,000 shares.
Risks and uncertainties
- Ongoing litigation risk from the securities class action filed by Kahn Swick & Foti could affect investor sentiment in the healthcare and capital markets sectors.
- Significant recent stock volatility, including a 54% decline over six months, highlights market risk for shareholders and potential pressure on liquidity and valuation perceptions.
- Mixed insider activity and analyst reactions create uncertainty around near-term market positioning for Corcept within the biotechnology and pharmaceuticals sector.
Investors and market observers should weigh the combination of an FDA milestone, divergent insider transactions, analyst reassessment, and ongoing litigation when assessing Corcepts near-term outlook. The companys valuation signals from InvestingPro suggest undervaluation under that specific Fair Value framework even as the market price remains well below the levels at which the CEO sold shares.